미국의 엑소좀 시장 규모, 점유율, 동향 분석 보고서 : 제품 및 서비스별, 용도별, 워크플로우별, 최종 용도별, 부문별 예측(2026-2033년)

U.S. Exosomes Market Summary

The U.S. exosomes market size was estimated at USD 115.6 million in 2025 and is projected to reach USD 716.8 million by 2033, growing at a CAGR of 25.75% from 2026 to 2033. Exosome applications are advancing, which is driving market growth. Technological advancements in exosome isolation and analytical procedures are contributing to market growth and are fueled by the increasing prevalence of cancer.

Increasing Prevalence of Cancer

The increasing prevalence of cancer is one of the key factors contributing to market growth over the forecast period. In 2025, an estimated over 2 million new cancer cases were diagnosed in the U.S. alone.

Exosomes have gained attention for their potential as biomarkers for early cancer detection, monitoring disease progression, and assessing therapeutic responses. With the global incidence of cancer on the rise, there is an increasing need for advanced diagnostic tools and targeted treatments, the development of which can be facilitated by exosome-based technologies.

U.S. Exosomes Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the U.S. exosomes market based on product & service, application, workflow, and end use:

• Product & Service Outlook (Revenue, USD Million, 2021 - 2033)
• Kits & reagents
• Instruments
• Services
• Workflow Outlook (Revenue, USD Million, 2021 - 2033)
• Isolation Methods
  • Ultracentrifugation
  • Immunocapture on beads
  • Precipitation
  • Filtration
  • Others
• Downstream Analysis
  • Cell surface marker analysis using flow cytometry
  • Protein Analysis using blotting & ELISA
  • RNA analysis with NGS & PCR
  • Proteomic analysis using mass spectroscopy
  • Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Cancer
• Neurodegenerative Diseases
• Cardiovascular Diseases
• Infectious Diseases
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biotechnology Companies
• Hospitals & Diagnostics Centers
• Academic & Research Institutes

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Application Segment
  • 1.1.2. Product & Service Segment
  • 1.1.3. Workflow Segment
  • 1.1.4. End Use Segment
• 1.2. Estimates and Forecast Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Primary Research
• 1.5. Information or Data Analysis:
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objective

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables & Trends

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Technological advancements in exosomes isolation and analytical procedures
    • 3.2.1.2. Advanced applications of exosomes
    • 3.2.1.3. Growth in strategic initiatives for exosome-based therapies
    • 3.2.1.4. Increasing prevalence of cancer
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Stringent regulations pertaining to approval
    • 3.2.2.2. Challenges associated with the implementation of exosome-based therapies
    • 3.2.2.3. Reduction in funding for biomedical research
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis

Chapter 4. U.S. Exosomes Market Product & Service Estimates & Trend Analysis

• 4.1. U.S. Exosomes Product & Service Dashboard
• 4.2. U.S. Exosomes Product & Service Movement Analysis
• 4.3. Kits & Reagents
  • 4.3.1. Kits & Reagents Market, 2021 - 2033 (USD Million)
• 4.4. Instruments
  • 4.4.1. Instruments Market, 2021 - 2033 (USD Million)
• 4.5. Services
  • 4.5.1. Services Market, 2021 - 2033 (USD Million)

Chapter 5. U.S. Exosomes Market Application & Trend Analysis

• 5.1. U.S. Exosomes Market Application Dashboard
• 5.2. U.S. Exosomes Market Application Movement Analysis
• 5.3. Cancer
  • 5.3.1. Cancer Market, 2021 - 2033 (USD Million)
• 5.4. Neurodegenerative Diseases
  • 5.4.1. Neurodegenerative Diseases Market, 2021 - 2033 (USD Million)
• 5.5. Cardiovascular Diseases
  • 5.5.1. Cardiovascular Diseases Market, 2021 - 2033 (USD Million)
• 5.6. Infectious Diseases
  • 5.6.1. Infectious Diseases Market, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Other Applications Market, 2021 - 2033 (USD Million)

Chapter 6. U.S. Exosomes Market Workflow Estimates & Trend Analysis

• 6.1. U.S. Exosomes Market Workflow Dashboard
• 6.2. U.S. Exosomes Market Workflow Movement Analysis
• 6.3. Isolation Methods
  • 6.3.1. Isolation Methods Market, 2021 - 2033 (USD Million)
  • 6.3.2. Ultracentrifugation
    • 6.3.2.1. Ultracentrifugation Market, 2021 - 2033 (USD Million)
  • 6.3.3. Immunocapture On Beads
    • 6.3.3.1. Immunocapture On Beads Market, 2021 - 2033 (USD Million)
  • 6.3.4. Precipitation
    • 6.3.4.1. Precipitation Market, 2021 - 2033 (USD Million)
  • 6.3.5. Filtration
    • 6.3.5.1. Filtration Market, 2021 - 2033 (USD Million)
  • 6.3.6. Others
    • 6.3.6.1. Other Isolation Methods Market, 2021 - 2033 (USD Million)
• 6.4. Downstream Analysis
  • 6.4.1. Downstream Analysis Market, 2021 - 2033 (USD Million)
  • 6.4.2. Cell Surface Marker Analysis Using Flow Cytometry
    • 6.4.2.1. Cell Surface Marker Analysis Using Flow Cytometry Market, 2021 - 2033 (USD Million)
  • 6.4.3. Protein Analysis Using Blotting & ELISA
    • 6.4.3.1. Protein Analysis Using Blotting & ELISA Market, 2021 - 2033 (USD Million)
  • 6.4.4. RNA Analysis With NGS & PCR
    • 6.4.4.1. RNA Analysis With NGS & PCR Market, 2021 - 2033 (USD Million)
  • 6.4.5. Proteomic Analysis Using Mass Spectrometry
    • 6.4.5.1. Proteomic Analysis Using Mass Spectrometry Market, 2021 - 2033 (USD Million)
  • 6.4.6. Others
    • 6.4.6.1. Other Downstream Analysis Market, 2021 - 2033 (USD Million)

Chapter 7. U.S. Exosomes Market End Use Estimates & Trend Analysis

• 7.1. U.S. Exosomes Market End Use Dashboard
• 7.2. U.S. Exosomes Market End Use Movement Analysis
• 7.3. Pharmaceutical & Biotechnology Companies
  • 7.3.1. Pharmaceutical & Biotechnology Companies Market, 2021 - 2033 (USD Million)
• 7.4. Hospitals & Diagnostics Centers
  • 7.4.1. Hospitals & Diagnostics Centers Market, 2021 - 2033 (USD Million)
• 7.5. Academic & Research Institutes
  • 7.5.1. Academic & Research Institutes Market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Categorization
• 8.2. Company Market Position Analysis, 2025
• 8.3. Company Profiles
  • 8.3.1. Danaher
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Product benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. Thermo Fisher Scientific, Inc.
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Product benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Hologic Inc.
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Product benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. Bio-Techne
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. RoosterBio, Inc
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. Fujifilm Holdings Corporation
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Lonza
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Miltenyi Biotec
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. QIAGEN
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. CellBio Scientific
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives